ClinicalTrials.gg
RecruitingNCT06961149Updated May 7, 2025

Linked-Color Imaging Versus Indigo Carmine Pump Spraying on the Colorectal Adenoma Detection Rate

An interventional study of Chromoendoscopy with indigo carmine solution spray and Linked-color imaging endoscopy in Colonic Polyps, Adenomatous Polyps and Adenoma Detection Rate, sponsored by Shandong University. Recruiting at 1 site in China. Open to participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-05-07.

Sponsored by Shandong University · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
352
Allocation
Randomized
Ages
45 Years to 85 Years
Sex
All
01

Study summary

Detection and removal of polyps during colonoscopy is crucial for the prevention of colorectal cancer. Indigo carmine spraying up to the colonic mucosa could probably increase the adenoma detection rate, but considering the long withdrawal time of the endoscope and the resulting increase in time and cost. Linked-color imaging (LCI) is a newly developed image-enhanced endoscopy technology. It relies on wave length optimization of three colors (red, green, and blue) to make the lesions appear fuller. LCI improves the visibility of colorectal adenomas and polyps and may increase the detection rate of lesions. In order to explore the clinical application value of Linked-color imaging endoscopy, we performed a prospective, randomized controlled trial to compare adenoma detection rate of Linked-color imaging endoscopy and indigo carmine chromoendoscopy.

Read the detailed description

If patients scheduled for colonoscopy meet the inclusion criteria but not the exclusion criteria, participants will be recruited to the study and randomized to one of two groups. Group allocation was revealed to endoscopists upon confirmation of cecal intubation. participants in Group A (treatment group) will undergo colonoscopy with LCI. participants in Group B (control group) will undergo spraying indigo carmine solution during withdrawal process. Any lesions found during the procedure will be removed and sent for pathological examination. The investigator will record the participants' general information (such as gender, age, symptoms, body mass index,etc.), colonoscopy data (such as duration etc.), and lesion characteristics (such as location, morphology, histopathological classification, etc.). All data were analyzed according to the ITT analysis, and the PP analysis was performed for all outcomes. Continuous variables were presented as means ± standard deviation (SD), and compared using Independent Samples t test. Categorical variables were expressed as frequency counts (percentages) and analyzed using Pearson's chi-square test or the Fisher exact test. Statistical analyses were performed using SPSS 27.0. Statistical significance was defined as P \< 0.05.

02

Conditions studied

  • Colonic Polyps
  • Adenomatous Polyps
  • Adenoma Detection Rate
  • Chromoendoscopy
  • Colorectal Neoplasms

Keywords

  • Adenoma Detection Rate
  • Linked-color imaging
  • Chromoendoscopy
  • Colonoscopy
  • Indigo Carmine
03

In context

Colonic Polyps

377 studies on the registry are indexed under Colonic Polyps; 57 are open to participants now.

This study's planned enrollment of 352 is above the median of 274 across 250 interventional studies indexed under Colonic Polyps.

Browse Colonic Polyps studies →

Lead sponsor

Shandong University is the lead sponsor of 292 studies on the registry; 60 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 45 and 85 years
  2. Patients with a history of colorectal adenoma
  3. Patients whose first-degree relatives have a history of colorectal cancer or colorectal adenoma
  4. Patients with gastrointestinal symptoms (abdominal pain, bloody stool, chronic diarrhea or constipation, Unexplained anemia or weight loss;
  5. Patients with positive Fecal Immunochemical Test

Exclusion criteria

Exclusion Criteria:

  1. Patients with pregnancy, inflammatory bowel disease, familial adenomatosis polyposis, suspected CRC; intestinal obstruction, coagulopathy
  2. Patients with aspirin, clopidogrel or other anticoagulants/ antiplatelet drugs intake within 7 days
  3. Patents previous colorectal resection
  4. Patients with failed cecal intubation
  5. Patients with inadequate bowel preparation quality (BBPS≤5)
  6. Patients who refuse to participate or to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
352 participants (estimated)

Study arms

  • Experimental
    Linked-color imaging endoscopy

    Patients in this group will be carefully observed with LCI endoscopy during the colonoscopy withdraw.

    Procedure: Linked-color imaging endoscopy

  • Active comparator
    Chromoendoscopy with indigo carmine solution spray

    Patients in this group will be carefully observed with spraying indigo carmine solution during the colonoscopy withdraw.

    Procedure: Chromoendoscopy with indigo carmine solution spray

Interventions

  • ProcedureChromoendoscopy with indigo carmine solution spray

    Patients will undergo chromoendoscopy with spraying indigo carmine.

  • ProcedureLinked-color imaging endoscopy

    Patients will undergo Linked-color imaging endoscopy.

06

What researchers measure

Primary outcomes

  1. adenoma detection rate(ADR)

    adenoma detection rate (ADR) defined as the percentage of patients with at least one histologically confirmed adenomatous polyp detected and resected during colonoscopy.

    Time frame: Periprocedural

Secondary outcomes

  1. detected rate of different lesions

    detected rate of different lesions(advanced adenoma, sessile serrated lesion) adenoma per colonoscopy (APC) withdrawal time adverse event rates

    Time frame: Periprocedural

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jan 2026, 9 months after the start.

Of 132 non-industry interventional studies with no phase under Colonic Polyps, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's planned 9 months is below that.

Counting every sponsor, half of 149 studies reached it within 17 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2025
First posted
May 7, 2025
StartActual
Apr 8, 2025
Primary completionEst.
Jan 31, 2026
CompletionEst.
Apr 1, 2026
Last update
May 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06961149
Responsible party
Yanqing Li (Director, Shandong University) — Principal investigator
First posted
May 7, 2025
Start date
Apr 8, 2025
Primary completion
Jan 31, 2026 (estimated)
Completion
Apr 1, 2026 (estimated)
Last update
May 7, 2025

Study contacts

Rui Ji MD PHD
Contact
qljirui@email.sdu.edu.cn
+86-18560086103
Rui Ji MD PHD, +86-18560086103
Contact
qljirui@email.sdu.edu.cn

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion